Roche

With biosimilar threat under control (for now), Roche savors demand for its new drugs
With biosimilar threat under control (for now), Roche savors demand for its new drugs
Endpoints
Roche
M&A
Spark Therapeutics
China
Flag link:
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Skin Disease
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Skin Disease
BioSpace
Roche
clinical trials
Rituxan/MabThera
MMF
pemphigus vulgaris
Flag link:
Roche vice chairman says short-term profit hunger 'destroyed the planet'
Roche vice chairman says short-term profit hunger 'destroyed the planet'
Yahoo/Reuters
Roche
environmental concerns
Flag link:
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Pharmafile
Novartis
clinical trials
ligelizumab
Roche
Xolair
chronic urticaria
Flag link:
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Flag link:
After more than a year, Gilead finds new chief medical officer
After more than a year, Gilead finds new chief medical officer
Biopharma Dive
Gilead Sciences
Roche
Genentech
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:
Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders
Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders
Pharmaceutical Business Review
Roche
FDA
Rituxan
eosinophilic granulomatosis with polyangiitis
microscopic polyangiitis
Flag link:
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Fierce Pharma
M&A
UK
Spark Therapeutics
Roche
antitrust
CMA
Flag link:
Roche AI Program Can Predict Progression of Diabetic Retinopathy
Roche AI Program Can Predict Progression of Diabetic Retinopathy
BioSpace
artificial intelligence
Roche
Genentech
diabetic retinopathy
deep learning
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
Roche Packs New FDA-Approved Test in Its Arsenal
Roche Packs New FDA-Approved Test in Its Arsenal
Medical Devices and Diagnostics Industry
Roche
Babesia test
Babesia DNA
Babesia RNA
diagnostics
Flag link:
After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII
After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII
Endpoints
Roche
Gazyva
lupus nephritis
Flag link:
Roche and Celgene set for battle in acute myelogenous leukaemia
Roche and Celgene set for battle in acute myelogenous leukaemia
EP Vantage
Celgene
Roche
AML
acute myeloid leukemia
CC-486
Venclexta
Flag link:
ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%
ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%
Fierce Pharma
Roche
Ocrevus
multiple sclerosis
Flag link:
Renal Cell Carcinoma Space in Focus: Some Key Developments
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Flag link:
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
Pharmaforum
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Flag link:
Roche's satralizumab cuts relapse risk in rare disease phase 3
Roche's satralizumab cuts relapse risk in rare disease phase 3
Fierce Biotech
Roche
satralizumab
neuromyelitis optica spectrum disorder
Flag link:

Pages